Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · IEX Real-Time Price · USD
4.250
-0.100 (-2.30%)
At close: Jul 19, 2024, 4:30 PM
4.170
-0.080 (-1.88%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Autolus Therapeutics Employees
Autolus Therapeutics had 463 employees as of December 31, 2023. The number of employees increased by 64 or 16.04% compared to the previous year.
Employees
463
Change (1Y)
64
Growth (1Y)
16.04%
Revenue / Employee
$22,672
Profits / Employee
-$477,888
Market Cap
1.13B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 463 | 64 | 16.04% |
Dec 31, 2022 | 399 | 75 | 23.15% |
Dec 31, 2021 | 324 | -52 | -13.83% |
Dec 31, 2020 | 376 | 86 | 29.66% |
Dec 31, 2019 | 290 | 124 | 74.70% |
Sep 30, 2018 | 166 | 40 | 31.75% |
Dec 31, 2017 | 126 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Owens & Minor | 22,200 |
Artivion | 1,500 |
AtriCure | 1,050 |
Maravai LifeSciences Holdings | 650 |
Silk Road Medical | 474 |
Relay Therapeutics | 323 |
Arcutis Biotherapeutics | 296 |
Ironwood Pharmaceuticals | 267 |
AUTL News
- 5 weeks ago - Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress - GlobeNewsWire
- 7 weeks ago - Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO - GlobeNewsWire
- 3 months ago - Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - GlobeNewsWire
- 4 months ago - Autolus Therapeutics Announces Changes to its Board of Directors - GlobeNewsWire
- 4 months ago - Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 4 months ago - Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site - GlobeNewsWire